Tumor Models Archives - Page 6 of 11

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses...

OncoWuXi Express: FaDu ATM Knockout Tumor model

OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well...

Immune-Avatar Humanized Tumor Models

To support antitumor efficacy testing and address the challenges of clinical translatability, WuXi AppTec offers extensive panels of immune-avatar humanized...

Expanded Applications of PDX Models

Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard...

Leveraging Animal Models to Combat Drug Resistance in Cancer Therapy

Cancer, globally recognized as a significant threat to public health, can be effectively controlled in its early stages through chemotherapy, targeted...

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...

Colitis-Associated Cancer Mouse Model

The cumulative impact of chronic inflammation in patients with inflammatory bowel disease (IBD) predisposes them to the development of IBD-associated...

Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment

SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by...

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

DNA-dependent protein kinase (DNA-PK) plays an important role in the overall survival and proliferation of cells, making this enzyme an...

Knowledge Library